Information Provided By:
Fly News Breaks for March 30, 2016
ACAD
Mar 30, 2016 | 08:24 EDT
Leerink analyst Paul Matteis views approval of ACADIA's treatment of Parkinson's disease psychosis as "very likely" after an FDA panel voted 12-2 in favor of the drug's risk/benefit. The analyst believes a black box label is also very likely given panel commentary and FDA precedent, which he sees as largely in-line with consensus. Matteis reiterates an Outperform rating on ACADIA with a $40 price target.
News For ACAD From the Last 2 Days
There are no results for your query ACAD